Product Description
Mechanisms of Action: Btk Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Bristol-Myers Squibb
Company Location: NEW YORK NY 10016
Company CEO: Giovanni Caforio
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Arthritis, Rheumatoid
Phase 1: Lymphocytic Chronic B-Cell Leukemia|Lymphoma, B-Cell|Chronic Lymphoid Leukemia|Healthy Volunteers|Waldenstrom Macroglobulinemia|Lymphoma, Non-Hodgkin|Diffuse Large B-Cell Lymphoma|Follicular Lymphoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| CC-122-DLBCL-001 | P1 |
Terminated |
Diffuse Large B-Cell Lymphoma|Follicular Lymphoma |
2023-12-12 |
44% |
2024-01-19 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
| CC-292-CLL-001 | P1 |
Completed |
Lymphocytic Chronic B-Cell Leukemia|Chronic Lymphoid Leukemia |
2019-01-23 |
12% |
2019-05-24 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
| CC-292-RA-001 | P2 |
Completed |
Arthritis, Rheumatoid |
2016-01-01 |
2019-03-20 |
Treatments |
|
| CC-292-CLL-002 | P1 |
Completed |
Chronic Lymphoid Leukemia|Lymphocytic Chronic B-Cell Leukemia|Lymphoma, B-Cell |
2015-12-01 |
2019-03-19 |
Treatments |
|
| AVL-292-003 | P1 |
Completed |
Chronic Lymphoid Leukemia|Lymphoma, B-Cell|Lymphoma, Non-Hodgkin|Lymphocytic Chronic B-Cell Leukemia|Waldenstrom Macroglobulinemia |
2015-06-26 |
2019-11-09 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments |
|
| CLEAR | P1 |
Completed |
Lymphoma, B-Cell |
2014-11-01 |
2019-03-19 |
Treatments |
|
| CC-292-CP-002 | P1 |
Completed |
Healthy Volunteers |
2014-09-26 |
2020-08-14 |
Primary Endpoints |
|
| AVL-292-004 | P1 |
Completed |
Healthy Volunteers |
2012-10-08 |
2019-11-05 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |